Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
Patents for C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
06/2005
06/22/2005EP1154774B1 Quinazoline derivatives as angiogenesis inhibitors
06/22/2005EP1040111B1 Integrin receptor antagonists
06/22/2005CN1630658A Variolin derivatives as anti-cancer agents
06/22/2005CN1630657A Deazapurines and uses thereof
06/22/2005CN1630656A Dihydropyrazolopyridine compounds and pharmaceutical use thereof
06/22/2005CN1630655A Dual action antibiotics
06/22/2005CN1630653A Pyrazolyl-substituted heterocycles and their use as phytosanitary products
06/22/2005CN1630651A Novel gamma secretase inhibitors
06/22/2005CN1630632A Aromatic amino acid derivates and medicinal compositions
06/22/2005CN1629165A Lanthanum amino acid complex and its preparing process and application
06/22/2005CN1629162A Unidimensional linear bieuropium(III) monohydrate and its preparation method
06/22/2005CN1629161A Methane sulfonic acid dolasetron crystallographic form and its preparation method
06/22/2005CN1629158A Pyran derivative
06/22/2005CN1207294C Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
06/21/2005US6909002 Nitrogen compounds such as N-Cyclopropyl-1-(3-(6-(1-hydroxy-1 -methylethyl)-1-oxidopryidin-3-yl)phenyl)-4-oxo-1,4-dihydro-1, 8-naphthyridine-3-carboxyamide, formed condensation and amidation in the presence of catalysts; drugs
06/21/2005US6909001 Cyclization of salicaldehyde with 3-(2-furyl)-3-oxopropane-nitrile, to form 2-amino-4-(2-furyl)-5H-chromeno(2,3-b) pyridine-3-carbonitrile, used as mitogen activated protein kinase inhibitors
06/21/2005US6908935 Calcium receptor modulating agents
06/21/2005US6908930 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors
06/21/2005US6908929 Central nervous system disorders
06/21/2005US6908926 Substituted imidazoles, their preparation and use
06/21/2005US6908922 Linear cyclic ureas
06/21/2005US6908921 Quinoxalinone derivatives as bradykinin B1 antagonists
06/21/2005CA2250372C 6-phenylpyridyl-2-amine derivatives
06/16/2005WO2005054246A2 Amine derivatives having a tyrosine-kinase-inhibiting effect
06/16/2005WO2005054244A2 Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
06/16/2005WO2005054243A1 Diazabicyclononene derivatives and their use as renin inhibitors
06/16/2005WO2005054242A1 Muscarinic agents as therapeutic compounds
06/16/2005WO2005054241A2 Phenanthridinium derivatives as dna binding agents
06/16/2005WO2005054240A1 Polymorphs of 1-cyclopropyl-7-([s,s]-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof
06/16/2005WO2005054239A1 2-aminopyrimidine derivatives
06/16/2005WO2005054238A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
06/16/2005WO2005054237A1 1h-imidazoquinoline derivatives as protein kinase inhibitors
06/16/2005WO2005054236A1 Substituted quinolines for the treatment of cancer
06/16/2005WO2005054232A1 1-acetic acid-indole, -indazole and-benzimidazole derivatives usful for the treatment of respiratory disorders
06/16/2005WO2005054230A1 Azole-based kinase inhibitors
06/16/2005WO2005054203A1 Quinoline derivatives substituted by aliphatic amino groups, the preparation and the pharmaceutical use thereof
06/16/2005WO2005054183A2 Quinolinone based protein kinase inhibitors
06/16/2005WO2005053692A1 Advanced quinolinone based protein kinase inhibitors
06/16/2005WO2005044818A3 Imidazo[1,2-a]pyridine anxiolytics
06/16/2005WO2005032481A3 Quinazoline derivatives as medicaments
06/16/2005WO2005026145A3 Quinolone antibacterial agents
06/16/2005WO2005025293A3 Fused ring heterocycles as potassium channel modulators
06/16/2005WO2005021544A3 N3-substituted imidazopyridine-derivatives as c-kit inhibitors
06/16/2005WO2005016255A3 Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
06/16/2005WO2005013892A3 Hydrolytically-resistant boron-containing therapeutics and methods of use
06/16/2005WO2005007658A3 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
06/16/2005WO2004110991A3 PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
06/16/2005WO2004073615A3 Deazaflavin compounds and methods of use thereof
06/16/2005US20050131236 Central nervous ystem disorders; neurodegenerative disorders; muscle contraction; endocrine diseases
06/16/2005US20050131231 Process for preparing cyclic N-substituted alpha-imino carboxlic acids
06/16/2005US20050131226 Rearranged pentanols, a process for their production and their use as anti-inflammatory agents
06/16/2005US20050131177 1-Alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators
06/16/2005US20050131042 HIV protease inhibiting compounds
06/16/2005US20050131017 HIV protease inhibiting compounds
06/16/2005US20050131012 Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
06/16/2005US20050131011 Antiinflammatory agents; viricides against human t-cell/lymphoma virus or retroviruses
06/16/2005US20050131010 Central nervous system disorders; antibiotics; viricides; antitumor agents; psychological disorders
06/16/2005US20050131009 Urea substituted imidazoquinolines
06/16/2005US20050131004 8-[2-(6,6-Dimethyl-bicyclo[3.1.1]hept-2-yl)-ethyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one and derivatives; treating metabolic, gastrointestinal, urogenital, renal, cardiovascular, opthalmological, respiratory, and immunological disorders and viral infections; especially diarrhea and visceral pain
06/16/2005US20050130996 5-(4-{3-chloro-4-(3-fluorobenzyloxy)-anilino}-6-quinazolinyl)-furan-2-carbaldehyde; selective inhibition of the protein tyrosine kinase activity, minimising side effects
06/16/2005US20050130984 Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
06/16/2005US20050130979 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders
06/16/2005US20050130977 Inhibitors of akt activity
06/16/2005US20050130976 Bicyclic inhibitors of MEK and methods of use thereof
06/16/2005US20050130972 Derivatives have a positive charge at the position corresponding to the anomeric position of a pyranose ring; active-site specific chaperones for mutant glucocerebrosidase
06/16/2005US20050130943 Bicyclic inhibitors of MEK and methods of use thereof
06/16/2005US20050127823 Material for organic electroluminescent devices and organic electroluminescent devices made by using the same
06/16/2005DE10354628A1 2-Ethyl-4,6-dimethyl-phenyl-substituierte Tetramsäure-Derivate 2-ethyl-4,6-dimethyl-phenyl-substituted tetramic acid derivatives
06/16/2005CA2547551A1 Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
06/16/2005CA2547547A1 Diazabicyclononene derivatives and their use as renin inhibitors
06/16/2005CA2546117A1 1h-imidazoquinoline derivatives as protein kinase inhibitors
06/16/2005CA2545425A1 Azole-based kinase inhibitors
06/16/2005CA2541691A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
06/15/2005EP1541575A1 Novel process for producing imidazo(1,2-b)pyridazine derivative
06/15/2005EP1541574A1 Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient
06/15/2005EP1541573A1 Novel crystals of triazaspiro 5.5 undecane derivative
06/15/2005EP1541572A1 Thioether substituted imidazoquinolines
06/15/2005EP1541571A1 Bicyclic unsaturated tertiary amine compound
06/15/2005EP1541558A1 Heterocyclic compound having hiv integrase inhibitory activity
06/15/2005EP1541551A1 2-cyano-4-fluoropyrrolidine derivative or its salt
06/15/2005EP1541176A1 Adhesive patch
06/15/2005EP1541148A1 Dpp-iv inhibitors
06/15/2005EP1541146A1 Zolpidem hemitartrate solvate
06/15/2005EP1539767A2 Opiate analogs selective for the delta-opioid receptor
06/15/2005EP1539766A1 Calcitonin gene related peptide receptor antagonists
06/15/2005EP1539765A1 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
06/15/2005EP1539764A1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
06/15/2005EP1539759A1 Use of and some novel imidazopyridines
06/15/2005EP1539758A1 Substituted pyrrolopyridines
06/15/2005EP1539757A1 Substituted pyrrolopyridines
06/15/2005EP1539756A2 Imidazopyridines as cyclin dependent kinase inhibitors
06/15/2005EP1539755A1 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
06/15/2005EP1539754A2 Benzimidazole quinolinones and uses thereof
06/15/2005EP1539753A2 Pyrazolo(3,4-b)pyridine compounds, and their use as phosphodiesterase inhibitors
06/15/2005EP1539752A1 Preparation of 1h-imidazo 4,5-c quinolin-4-amines via novel 1h-imidazo 4,5-c quinolin-4-cyano and 1h-imida zo 4,5-c quinolin-4-carboxamide intermediates
06/15/2005EP1539751A1 Process for the preparation of imidazo(1,2-a)pyridine-3-acetamides
06/15/2005EP1539750A1 Pyrazolopyridines as cyclin dependent kinase inhibitors
06/15/2005EP1539749A2 Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
06/15/2005EP1539748A1 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
06/15/2005EP1539742A1 Indole derivatives useful as histamine h3 antagonists
1 ... 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 ... 646